PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 08:22 UTC
-
New combo therapy aims to boost stomach cancer treatment before surgery
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery can safely treat stomach cancer. About 32 adults with resectable gastric or gastroesophageal junction cancer will receive this combination. The goa…
Matched conditions: PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: PATHOLOGIC STAGE IC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC